Has had a prior monoclonal antibody within 4 weeks prior to study Day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events (AEs) due to agents administered more than 4 weeks earlier; non-clinically significant adverse events may be considered as an exception after discussion with and approval by the principal investigatorXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (ie, ? Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.Xx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) =< 28 days prior to registration or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXCOHORT 1: Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXCOHORT 2: Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXSAFETY RUN-IN: Has had a prior monoclonal antibody within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXRANDOMIZED PHASE II CLINICAL TRIAL: Has had a prior monoclonal antibody within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to cycle 1 day 1 or who has not recovered (i.e. =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas received prior anti-cancer monoclonal antibody (mAb), chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or not recovered from adverse events due to a previously administered agentXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody within 4 weeks prior to study day 1 or has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agentXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.Xx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to registration or who has not recovered (i.e., =< grade 1 or baseline) from adverse events due to agents administered > 4 weeks priorXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPrior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or not recovered from an adverse event caused by mAbs administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatient has received a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or baseline) from adverse events due to a previously administered agentsXx_NEWLINE_xXHas had a prior monoclonal antibody within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPrior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to enrollment or who has not recovered from AEs due to mAb agents administered more than 4 weeks earlier.Xx_NEWLINE_xXHas received treatment with an anticancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 2 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study registration or who has not recovered (i.e. =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPrior anti-cancer monoclonal antibody =< 28 days prior to registration or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPrior treatment with a monoclonal antibody within 4 weeks prior to the first dose of MK-3475 or has not recovered (i.e. =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.Xx_NEWLINE_xXHas received a prior monoclonal antibody within 4 weeks prior to study day 1 or who has not recovered (i.e., ? grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 3 weeks prior to study day 1, or targeted small molecule therapy within 2 weeks prior to study day 1, or who has not recovered (i.e., ? grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXParticipants must not have had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or have not recovered (i.e. =< grade 1 at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., ? grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., ? grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.Xx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior, anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to Cycle 1/Day 1 or who has not recovered (i.e., ? Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.Xx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier\r\n* Note: The use of denosumab is an exception to this criterionXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., ? grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti?cancer monoclonal antibody (mAb) within 28 days prior to study day 1 or who has not recovered (i.e., ? grade 1 or at baseline) from adverse events due to agents administered more than 28 days earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.Xx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.Xx_NEWLINE_xXPrior anti-cancer monoclonal antibody (mAb) =< 4 weeks prior to registration or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks prior to registrationXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 14 days prior to on-study date or who has not recovered (i.e., ? grade 1 or baseline) from adverse events due to agents administered more than 4 weeks earlier; (subjects with ? grade 2 neuropathy are an exception to this criterion and may qualify for the study)Xx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) treatment within 4 weeks prior to study day 1 or who has not recovered (i.e., ? grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., ? grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had prior monoclonal antibody therapy within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events (AEs) due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or baseline) from adverse events (AEs) due to agents administered more than 28 days earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had prior anticancer therapy within 4 weeks of study day 1 or has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or to baseline) from adverse events due to agents administered more than 4 weeks earlier; note that denosumab for treatment for bone metastases is allowedXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXReceived an anti-cancer monoclonal antibody (mAb) within 4 weeks prior to the first dose of study treatment or who has not recovered (i.e. ?Grade 1 or baseline) from AEs due to agents administered more than 4 weeks earlier.Xx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 3 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 3 weeks earlier; if a patient has progressive or stable disease to prior regimen, rituximab is allowed up to 2 weeks prior to the initiation of study therapyXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXParticipants who have had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatient has received a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or baseline) from adverse events due to a previously administered agentsXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPrior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to the first dose of study drug or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agentXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) =< 4 weeks prior to registration or who has not recovered (i.e., =< grade 1 or at baseline level) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXSubjects must not have received a prior monoclonal antibody within 4 weeks prior to the first dose of study medication, and must have recovered (=< grade 1) from adverse events related to any anti-cancer agent administered > 4 weeks previous to the first dose of study medicationXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXAdministration of a monoclonal antibody within 4 weeks prior to initiating study treatment or has not recovered (i.e., =< grade 1 or at baseline) from adverse events (AEs) due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to such agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 (first day of SBRT treatment) or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXAnti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have not recovered (to =< grade 1 or baseline) from adverse events due to agents administered more than 4 weeks >= 28 days earlier are not eligibleXx_NEWLINE_xXReceived prior monoclonal antibody within 4 weeks prior to study day 1 or who has not recovered (i.e. =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (ie, =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior monoclonal antibody within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior monoclonal antibody within 4 weeks or 5 half-lives, whichever is shorter, prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior monoclonal antibody within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had prior monoclonal antibody within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier; toxicities that are disease related will not exclude patientsXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPrior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to first dose of MK-3475 or has not recovered (i.e., to =< grade 1 or baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatient has not recovered to grade 0-1 from adverse events due to prior chemotherapy, radiation, or biological cancer therapy (including monoclonal antibody [mAb])Xx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (i.e., ? Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.Xx_NEWLINE_xXAnti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior monoclonal antibody within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had prior anti-cancer monoclonal antibody within 4 weeks of Study Day 1 or who has not recovered from adverse events due to agents administered >4 weeks earlierXx_NEWLINE_xXHas not recovered (i.e., =< grade 1 or at baseline) from adverse events due to investigational or standard agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior monoclonal antibody within 4 weeks or 5 half-lives, which ever is shorter, prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.Xx_NEWLINE_xXSubject has had a prior monoclonal antibody within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior monoclonal antibody within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior monoclonal antibody within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier; denosumab is allowed as long as not < 1 week prior to study day 1 and not administered on day of MK-3475 infusionXx_NEWLINE_xXHas had a prior monoclonal antibody within 4 weeks prior to study day 1 or who has not recovered (i.e., ? grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPrior monoclonal antibody within 4 weeks prior to study day 1 or individuals who have not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXSubject has had a prior monoclonal antibody within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 3 weeks prior to study day 1, or targeted small molecule therapy within 2 weeks prior to study day 1, or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier, with the exception of lymphopenia or asymptomatic aberrancies of sodium, amylase, lipase or alkaline phosphataseXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anticancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or has not recovered (i.e. ? Grade 1 or at Baseline) from adverse events (AEs) due to agents administered more than 4 weeks earlier.Xx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 2 at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior monoclonal antibody within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXREGISTRATION TO TREATMENT (STEP 1): Patient must not have received a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study registration or have not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXREGISTRATION TO TREATMENT (STEP 2): Patient must not have received a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study registration or have not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior monoclonal antibody within 4 weeks prior to study day 1 or who has not recovered (i.e., ? grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 3 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 3 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to registration for protocol therapy or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXAny of the following:\r\n* Prior anti-cancer monoclonal antibody (mAb) =< 4 weeks prior to registrationXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 (excluding commercial or investigational anti-PD1 or anti-PD-L1 antibodies as single agents) or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier; patients who have autoimmune adverse events controlled by replacement therapy (i.e. hypothyroidism) due to previous treatment are eligible provided replacement therapy has been initiated and toxicity has returned to grade 1Xx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXDOSE ESCALATION COHORT: Prior monoclonal antibody within 4 weeks before study day 1 or not recovered (? grade 1 or at baseline) from adverse events (AEs) due to agents administered more than 4 weeks earlier; exception to this rule would be use of denosumabXx_NEWLINE_xXDOSE EXPANSION COHORT: Prior monoclonal antibody within 4 weeks before study day 1 or not recovered (? grade 1 or at baseline) from AEs due to agents administered more than 4 weeks earlier; exception to this rule would be use of denosumabXx_NEWLINE_xXPrior anti-cancer therapy with a monoclonal antibody (mAb) =< 4 weeks prior to registration OR failure to recover (to =< grade 1) from adverse events (AE) attributable to agents received > 4 weeks prior to registrationXx_NEWLINE_xXParticipants who have had a prior anti-cancer monoclonal antibody (mAb) within 2 weeks prior to cycle 1 day 1 or who have not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 2 weeks earlierXx_NEWLINE_xXHas had a prior chemotherapy, targeted small molecule therapy, or monoclonal antibody within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior monoclonal antibody within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXNon-small cell lung cancer patients only: has had a prior monoclonal antibody within 4 weeks prior to first protocol treatment or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior monoclonal antibody within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events (AEs) due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anticancer monoclonal antibody (mAb) within 4 weeks prior to first dose study therapy or who has not recovered (i.e., Grade ?1 or at baseline) from AEs due to mAbs administered >4 weeks earlierXx_NEWLINE_xXPrior monoclonal antibody within 4 weeks prior to study Day 1 (2 weeks for RS participants) or who has not recovered (i.e. ? Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier (2 weeks for RS participants).Xx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) for direct anti-neoplastic treatment within 4 weeks prior to the first dose of study drug (6 weeks for nitrosoureas or mitomycin C) or who has not recovered (i.e., ? Grade 1 or at Baseline) from adverse events (AEs) due to mAbs administered more than 4 weeks earlier.Xx_NEWLINE_xXHas had prior anti-myeloma therapy within 2 weeks prior to study start and has not recovered (i.e., ? Grade 1 or at Baseline) from adverse events due to a previously administered agentXx_NEWLINE_xXPrior anti-cancer monoclonal antibody within 4 weeks prior to first dose of study drug or has not recovered from adverse effects due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPrior anti-cancer monoclonal antibody (mAb) therapy within 4 weeks prior to Study Day 1, or not recovered from adverse eventsXx_NEWLINE_xXPrior anti-cancer therapy with a monoclonal antibody (mAb) within 4 weeks prior to study day 1 or not recovered from adverse events (improved to grade 1 or less) due to mAbs administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody within 4 weeks prior to study Day 1 or who has not recovered (i.e., ? Grade 1 or at baseline) from AEs due to agents administered more than 4 weeks earlier.Xx_NEWLINE_xXPrior anti-cancer monoclonal antibody within 4 weeks prior to first dose of study drug, or not recovered from adverse effects due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior monoclonal antibody within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior monoclonal antibody within 4 weeks prior to study Day 1 or who has not recovered (i.e., ?Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.Xx_NEWLINE_xXHas had a prior chemotherapy, targeted small molecule therapy, or monoclonal antibody (except bevacizumab) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier; wash out period for bevacizumab is 14 daysXx_NEWLINE_xXHas had a prior monoclonal antibody within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXReceived prior monoclonal antibody (mAb) within 4 weeks prior to study.Xx_NEWLINE_xXPrior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or has not recovered (i.e., =< grade 1 or at baseline) for adverse events (AEs) due to agents administered > 4 weeks earlierXx_NEWLINE_xXHas had monoclonal antibody therapy within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 at baseline; excludes alopecia and grade 2 neuropathy) from adverse events due to agent(s) administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., >= grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXParticipant has had a prior monoclonal antibody within 4 weeks prior to study Day 1 or who has not recovered (i.e. ? Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.Xx_NEWLINE_xXHas had a prior monoclonal antibody within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior monoclonal antibody within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events (AEs) due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior monoclonal antibody within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to prior therapiesXx_NEWLINE_xXHas had a prior monoclonal antibody within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior monoclonal antibody within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPrior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior monoclonal antibody within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPhase Ib: Received prior monoclonal antibody therapy other than bevacizumab within 4 weeks of study registration or who has not recovered (i.e., ? Grade 1 or at baseline) from adverse events of such agents administered more than 4 weeks earlier.Xx_NEWLINE_xXHas had a prior monoclonal antibody within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPrior anti-cancer monoclonal antibody (mAb) for direct anti-neoplastic treatment within 4 weeks prior to study Day 1 or who has not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior monoclonal antibody within 4 weeks prior to radiation therapy or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior monoclonal antibody within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier; denosumab is a prohibited medication on study and for 4 weeks prior to day 1Xx_NEWLINE_xXHas had a prior monoclonal antibody within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior monoclonal antibody within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatient has had a prior monoclonal antibody for a nonâ€“cancer therapy indication within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events (AEs) due to agents administered more than 4 weeks earlierXx_NEWLINE_xXAnti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPrior anti-cancer monoclonal antibody (mAb) therapy within 4 weeks prior to study Day 1, or not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPrior anti-cancer therapy with a monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or not recovered from adverse events due to mAbs administered more than 4 weeks earlierXx_NEWLINE_xXHas had prior monoclonal antibody therapy within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events (AEs) due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPrior monoclonal antibody within 4 weeks before study Day 1, or has not recovered from adverse events due to agents administered more than 4 weeks earlier.Xx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events (AE) due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior mAb within 4 weeks prior to study Day 1 or who has not recovered from adverse events due to agents administered more than 4 weeks earlier.Xx_NEWLINE_xXHas had a prior monoclonal antibody within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from AEs due to agents administered more than 4 weeks earlierXx_NEWLINE_xXTreatment with an anti-cancer monoclonal antibody within 4 weeks prior to day 1 or has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior monoclonal antibody within 4 weeks prior to study day 1 or who has not recovered (i.e. =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior monoclonal antibody within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior monoclonal antibody within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy, radiotherapy, monoclonal antibody (mAb), or targeted small molecule therapy within 4 weeks of study registration are not eligible; those who have not recovered from adverse events (grade 1 or baseline) due to such agents administered more than 4 weeks earlier are not eligibleXx_NEWLINE_xXPrior anti-cancer monoclonal antibody (mAb) =< 4 weeks prior to registration or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered >= 4 weeks prior to registrationXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPrior treatment with a monoclonal antibody within 4 weeks prior to enrollment or who has not recovered (i.e. ? Grade 1 or baseline grade) from adverse events due to agents administered more than 4 weeks earlier.Xx_NEWLINE_xXHas had a prior monoclonal antibody within 4 weeks prior to study day 1 or who has not recovered (i.e., =<, grade 1 or at baseline and other than alopecia) from adverse events due to agents administered more than 4 weeks earlier; exceptions to these criteria may be allowed at the discretion of the UNC PI for toxicities that are not expected to be exacerbated by pembrolizumab or nab-paclitaxelXx_NEWLINE_xXHas had a prior monoclonal antibody (mAb) within 4 weeks prior to first dose of study drug in the study or who has not recovered (i.e., ? Grade 1 or at baseline) from adverse events (AEs) due to agents administered more than 4 weeks earlier.Xx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHas had a prior monoclonal antibody within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xX